TFC Therapeutics
- Company typePrivate
- Founded2023
- HeadquartersNyack, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
TFC Therapeutics firmographics
Firmographics- Name
- TFC Therapeutics
- Legal name
- TFC Therapeutics
- Website
- https://tfctx.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
TFC Therapeutics industry classification
Industry- Product category
- Oncology Biologics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
Keywords
Where TFC Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Nyack
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
TFC Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Biopharmaceutical product revenue: Pre-revenue stage biotech company developing novel biologics for cancer treatment. Revenue model anticipated to include product sales of approved therapeutics, with potential licensing and partnership revenue streams typical of the biopharmaceutical industry.
Go-to-market motion1 record
Marketing channels1 record
TFC Therapeutics product offering
Product offeringCore offering
TFC Therapeutics is a pre-clinical stage biotechnology company developing novel biologic therapeutics designed to target and eliminate the key biological drivers of cancer recurrence and metastasis. The company blends early-stage cancer biology research with an innovative biologics platform approach to create next-generation treatments aimed at the most resilient cancers, with the goal of preventing cancer recurrence before it begins.
Product overview
TFC Therapeutics is a biotech company developing novel biologics to target and eliminate key drivers of cancer recurrence and metastasis. The company employs an innovative platform approach and technologies in cancer biology to develop next-generation treatments targeting the most resilient cancers. No specific named products or modules are identified in the available source data.
Differentiator
Problem solved
Functional benefit
Companies that use TFC Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
TFC Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
TFC Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights3 records
TFC Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Gilead Sciences: Major oncology biologics player through Kite Pharma (Yescarta, Tecartus CAR-T therapies) and Trodelvy antibody-drug conjugate. Operates broadly in oncology biologics and is the closest large-cap comparable for a novel biologics platform targeting cancer.
- Bristol-Myers Squibb: Large pharma with significant oncology biologics portfolio including CAR-T therapies (Breyanzi, Abecma) and immune-based biologics. Comparable as an incumbent developing biologic treatments for hematologic and solid tumors.
- Novartis: Develops Kymriah, the first FDA-approved CAR-T therapy, plus a broad oncology biologics pipeline including radioligand therapy (Pluvicto). Comparable as a leading oncology biologics platform incumbent.
- Regeneron Pharmaceuticals: Major biotech with a VelocImmune antibody platform producing multiple oncology biologics (Libtayo, etc.) and a pipeline of novel engineered antibodies for cancer. Comparable as an antibody-biologics platform incumbent.
- Pfizer: Large pharma with a substantial oncology biologics portfolio (including biologics acquired via Seagen) and active investment in novel cancer therapeutics. Comparable as a major incumbent that could be a potential acquirer or partner for a pre-clinical platform.
Direct peers
- Adaptimmune Therapeutics: Clinical-stage biotech developing engineered T-cell receptor (TCR-T) therapies for solid tumors. Most direct comparable as a cell-based biologics platform targeting cancer drivers, with similar modality and pre-clinical-to-clinical stage profile.
- Allogene Therapeutics: Clinical-stage biotech developing allogeneic ('off-the-shelf') CAR-T cell therapies for cancer. Directly comparable as a next-generation cell therapy biologics platform targeting hematologic and solid tumor indications.
- Caribou Biosciences: Clinical-stage biotech developing allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable as a platform biotech applying novel biological engineering to develop cell-based cancer therapeutics.
- CRISPR Therapeutics: Clinical-stage gene-editing biotech developing Casgevy (the first CRISPR-based therapy) and a pipeline of gene-edited cell therapies for cancer. Comparable as a platform biotech using novel biological engineering for oncology applications.
Emerging players
- Beam Therapeutics: Clinical-stage biotech developing base-editing therapies for cancer and rare diseases. Comparable as an emerging player building a novel biological platform for targeted cancer treatment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
TFC Therapeutics social profiles
Digital presenceTFC Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
TFC Therapeutics leadership team
Management profileNumber of profiles
TFC Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TFC Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TFC Therapeutics
What does TFC Therapeutics do?
TFC Therapeutics is a pre-clinical stage biotechnology company developing novel biologic therapeutics designed to target and eliminate the key biological drivers of cancer recurrence and metastasis. The company blends early-stage cancer biology research with an innovative biologics platform approach to create next-generation treatments aimed at the most resilient cancers, with the goal of preventing cancer recurrence before it begins.
Is TFC Therapeutics a public or private company?
TFC Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was TFC Therapeutics founded?
TFC Therapeutics was founded in 2023. It employs 1 to 10 people.
Where is TFC Therapeutics based?
TFC Therapeutics is headquartered in Nyack, United States, in the North America region.
How does TFC Therapeutics make money?
One revenue line is on record: biopharmaceutical product revenue.
Who are TFC Therapeutics's main competitors?
Broad incumbents on record are Gilead Sciences, Bristol-Myers Squibb, Novartis, Regeneron Pharmaceuticals and Pfizer. Direct peers are Adaptimmune Therapeutics, Allogene Therapeutics, Caribou Biosciences and CRISPR Therapeutics. Beam Therapeutics is listed as an emerging player.
Does TFC Therapeutics have an API?
No public API is recorded for TFC Therapeutics.
What industry is TFC Therapeutics in?
TFC Therapeutics's product category is Oncology Biologics. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 541714 and its SIC code is 2836.